136 related articles for article (PubMed ID: 26670562)
21. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.
Toth RK; Warfel NA
Mol Cancer Ther; 2021 Jan; 20(1):3-10. PubMed ID: 33303645
[TBL] [Abstract][Full Text] [Related]
22. Rational cotargeting of Pim-1 and Akt in prostate cancer.
Toren P; Zoubeidi A
Expert Rev Anticancer Ther; 2013 Aug; 13(8):937-9. PubMed ID: 23984895
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
24. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
25. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.
Le X; Antony R; Razavi P; Treacy DJ; Luo F; Ghandi M; Castel P; Scaltriti M; Baselga J; Garraway LA
Cancer Discov; 2016 Oct; 6(10):1134-1147. PubMed ID: 27604488
[TBL] [Abstract][Full Text] [Related]
26. Pim family kinases enhance tumor growth of prostate cancer cells.
Chen WW; Chan DC; Donald C; Lilly MB; Kraft AS
Mol Cancer Res; 2005 Aug; 3(8):443-51. PubMed ID: 16123140
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.
Lantermann AB; Chen D; McCutcheon K; Hoffman G; Frias E; Ruddy D; Rakiec D; Korn J; McAllister G; Stegmeier F; Meyer MJ; Sharma SV
Cancer Res; 2015 Nov; 75(22):4937-48. PubMed ID: 26490646
[TBL] [Abstract][Full Text] [Related]
28. T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.
Wang Z; Li XM; Shang K; Zhang P; Wang CF; Xin YH; Zhou L; Li YY
Oncol Rep; 2013 Mar; 29(3):1245-51. PubMed ID: 23314349
[TBL] [Abstract][Full Text] [Related]
29. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
30. Pim-1 kinase as activator of the cell cycle pathway in neuronal death induced by DNA damage.
Zhang Y; Parsanejad M; Huang E; Qu D; Aleyasin H; Rousseaux MW; Gonzalez YR; Cregan SP; Slack RS; Park DS
J Neurochem; 2010 Jan; 112(2):497-510. PubMed ID: 19895669
[TBL] [Abstract][Full Text] [Related]
31. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
32. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
[TBL] [Abstract][Full Text] [Related]
34. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract][Full Text] [Related]
35. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1.
Kim JH; Kim WS; Yun Y; Park C
Cell Signal; 2010 Dec; 22(12):1858-63. PubMed ID: 20670681
[TBL] [Abstract][Full Text] [Related]
37. PIM kinases: From survival factors to regulators of cell motility.
Santio NM; Koskinen PJ
Int J Biochem Cell Biol; 2017 Dec; 93():74-85. PubMed ID: 29108877
[TBL] [Abstract][Full Text] [Related]
38. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
40. Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity.
Wang YY; Taniguchi T; Baba T; Li YY; Ishibashi H; Mukaida N
Cancer Sci; 2012 Jan; 103(1):107-15. PubMed ID: 21981263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]